[go: up one dir, main page]

WO2018008999A1 - Composition comprenant un extrait d'aster koraiensis ou une fraction de ce dernier en tant que principe actif servant à la régulation de la glycémie et à la prévention ou au traitement du diabète - Google Patents

Composition comprenant un extrait d'aster koraiensis ou une fraction de ce dernier en tant que principe actif servant à la régulation de la glycémie et à la prévention ou au traitement du diabète Download PDF

Info

Publication number
WO2018008999A1
WO2018008999A1 PCT/KR2017/007231 KR2017007231W WO2018008999A1 WO 2018008999 A1 WO2018008999 A1 WO 2018008999A1 KR 2017007231 W KR2017007231 W KR 2017007231W WO 2018008999 A1 WO2018008999 A1 WO 2018008999A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
diabetes
bee
composition
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/007231
Other languages
English (en)
Korean (ko)
Inventor
김진숙
김찬식
김정현
김영숙
이익수
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Oriental Medicine KIOM
Original Assignee
Korea Institute of Oriental Medicine KIOM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Oriental Medicine KIOM filed Critical Korea Institute of Oriental Medicine KIOM
Publication of WO2018008999A1 publication Critical patent/WO2018008999A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes

Definitions

  • the present invention relates to a composition for the prevention or treatment of diabetes mellitus comprising a bee anesthetist extract or fractions thereof as an active ingredient, specifically, for the control of blood glucose, or a prevention or treatment of diabetes mellitus including a bee herbicide extract or a fraction thereof as an active ingredient
  • a composition, a food composition, a feed composition and a method for preventing or treating diabetes using the pharmaceutical composition comprising a bee anesthetist extract or fractions thereof as an active ingredient, specifically, for the control of blood glucose, or a prevention or treatment of diabetes mellitus including a bee herbicide extract or a fraction thereof as an active ingredient
  • a composition, a food composition, a feed composition and a method for preventing or treating diabetes using the pharmaceutical composition are examples of preventing or treating diabetes using the pharmaceutical composition.
  • Diabetes is a disease in which abnormally high blood glucose levels are constantly increasing.
  • Type 1 diabetes is caused by the destruction of the pancreatic insulin-producing beta cells due to autoimmune diseases.
  • Type 2 diabetes is caused by insulin secretion of pancreatic beta cells and insulin target cells such as liver, muscle, and adipose tissue. Insulin resistance (impaired reactivity to insulin) and the like are related to the etiology. Diabetes is one of the world's most prevalent adult diseases. In 2009, the American Medical Association (JAMA) said that the number of diabetics in the world today is more than 240 million people and will increase to 380 million by 2025. It is announced. Recently, with the rapid economic growth in Korea, the prevalence of diabetes reaches 10%, and in particular, the onset of diabetes is being brought to the young, middle and old age.
  • JAMA American Medical Association
  • the overseas market and research progress of veterinary medicine targeting pets is exploding.
  • the overseas veterinary medicine market is valued at $ 23 billion (about 25 trillion won) as of 2014, which is 40 times the size of the domestic market, growing about 4% annually.
  • Pets are also suffering from the same diseases as humans, but there is no professional and appropriate countermeasure, so they are using medicines for humans.
  • steady management is essential for the prevention or treatment of diabetes in order to maintain blood sugar normally at the beginning of diabetes before the production of excessive final glycated products.
  • Insulin now commonly prescribed for diabetics, can cause side effects of hypoglycemic shock, edema and congestive heart failure throughout the body. It also causes local allergic reactions of the skin due to continuous insulin injections. Accordingly, studies on natural materials are actively conducted as candidate materials for preventing, improving and treating diabetes, preventing diabetes including ginseng fruit extract (Korean Patent No. 2016-0000041) as a natural extract as an active ingredient, Improved or therapeutic compositions have been developed.
  • Aster koraiensis is a Korean native plant belonging to the chrysanthemum family, which is planted for ornamental purposes. It grows mainly in marshes. Its height is 50 ⁇ 60cm, and the leaves attached to the roots are lost when flowering. The leaves on the stem are shifted and lanceolate, with fine jagged teeth on the edges, and become smaller and lined up. Flowers bloom in June-October. Duhwa is light purple, 4-5cm in diameter, hanging on one end of stem and branch. Fruits are aquatic, bassos, ripen in November. Young sprouts are used as salads and herbs, and they are used for the treatment of seawater, phlegm, asthma, etc., but there have been no reports on the effects of diabetes mellitus according to hypoglycemia or glycemic control.
  • the present inventors conducted research to develop a prophylactic or therapeutic agent for diabetes using natural products. As a result, it was confirmed that bee anesthetist extract or fractions thereof can treat diabetes by exhibiting a hypoglycemic or modulating effect, thereby completing the present invention.
  • One object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of diabetes mellitus comprising a bee odor an extract or fractions thereof as an active ingredient.
  • Another object of the present invention to provide a food composition for the prevention or improvement of diabetes mellitus including a bee herb extract or fractions thereof as an active ingredient.
  • Yet another object of the present invention is to provide a method for preventing or treating diabetes, comprising administering the composition to a subject.
  • Another object of the present invention is to provide a feed additive for the prevention or improvement of diabetes mellitus including a bee odor and an extract thereof as an active ingredient.
  • Yet another object of the present invention is to provide the use of the bee anesthetist extract or fractions thereof for the manufacture of a medicament for the prevention or treatment of diabetes.
  • Beetle anesthetic extract of the present invention promotes glucose absorption of adipocytes and thus lowers blood sugar, and thus can be usefully used for the prevention or treatment of diabetes.
  • the composition of the present invention is derived from natural products, it can be safely used without side effects in the prevention, treatment and improvement of diabetes.
  • One aspect of the present invention for achieving the above object provides a pharmaceutical composition for the prevention or treatment of diabetes mellitus comprising a bee odor extract or fractions thereof as an active ingredient.
  • Another aspect of the present invention for achieving the above object provides the use of the bee anesthetized extract or fractions thereof for the manufacture of a medicament for the prevention or treatment of diabetes.
  • the honey bee anesthetized extract by promoting glucose absorption of adipocytes by confirming the effect of lowering blood sugar, it was confirmed that the extract can be used as an active ingredient of diabetes treatment.
  • beetle odor refers to a domestic native plant belonging to the chrysanthemum family having the scientific name of Aster koraiensis . Young sprouts are used as salads and herbs, and are used for the treatment of seawater, phlegm and asthma. However, the effect of bee anesthesia on the hypoglycemic or glycemic control effect of the diabetes is not known at all, and was first identified by the present inventors.
  • the roots, stems, leaves, fruits, flowers, etc. of the hummingbird can be used for the prevention or treatment of diabetes mellitus, more specifically, leaves and / or stems can be used, as long as it has a prevention or treatment effect of diabetes Is not particularly limited thereto.
  • the hummingbird odor can be purchased commercially, or may be used collected or cultivated in nature.
  • extract refers to extracts obtained by extracting and processing the bee odor, diluents and concentrates of the extracts, dried products obtained by drying the extracts, modifiers and purified products of the extracts, and mixtures thereof. And extracts of all formulations that can be formed using extracts.
  • the method of extracting the hummingbird odor is not particularly limited, and may be extracted according to a method commonly used in the art.
  • the type of extraction solvent used to extract the bee odor is not particularly limited, and any solvent known in the art may be used.
  • Non-limiting examples of the extraction solvent may include water, alcohols having 1 to 4 carbon atoms or mixed solvents thereof, and these may be used alone or in combination of one or more thereof.
  • ethanol may be used, but is not limited thereto.
  • the ethanol may be 0.1 to 99.99% (v / v), specifically 30 to 90% (v / v), and more specifically 80% (v / v) ethanol. May be, but is not limited to such.
  • the bee odorous extract may be a bee odorous 80% (v / v) ethanol extract or water extract.
  • the bee odorless ethanol extract after extracting the bee odorous leaf alone, or the bee odorous leaf and stem pulverized with ethanol, it can be concentrated under reduced pressure and lyophilized to prepare a bee odor ethanol extract.
  • fraction refers to the result obtained by performing fractionation to separate a specific component or a specific group of components from a mixture comprising several various components.
  • the fractionation method of obtaining the fraction in the present invention is not particularly limited, and may be performed according to a method commonly used in the art.
  • Non-limiting examples of the fractionation method include a solvent fractionation method performed by treating various solvents, an ultrafiltration fractionation method performed through an ultrafiltration membrane having a constant molecular weight cut-off value, and various chromatography (size, charge, hydrophobicity). Or chromatographed fractions), and combinations thereof, which are prepared for separation according to affinity.
  • a method of obtaining a fraction from the extract by treating a predetermined solvent with an extract obtained by extracting the bee sting odor of the present invention are prepared for separation according to affinity.
  • the kind of the fractionation solvent used to obtain the fraction in the present invention is not particularly limited, and any solvent known in the art may be used.
  • Non-limiting examples of the fractionation solvents include polar solvents such as water and alcohols having 1 to 4 carbon atoms; Nonpolar solvents such as hexane, ethyl acetate, chloroform and dichloromethane; Or a mixed solvent thereof. These may be used alone or in combination of one or more thereof, but is not limited thereto.
  • hexane, ethyl acetate, butanol or water may be used alone or in combination of one or more thereof, but is not limited thereto. It doesn't happen.
  • extract or fraction may be prepared and used in the form of a dry powder after extraction, but is not limited thereto.
  • diabetes refers to metabolic diseases such as insufficient insulin secretion or normal function. It is characterized by high blood glucose, which increases the concentration of glucose in the blood, and causes various symptoms and signs due to high blood sugar and releases glucose into the urine.
  • prevention refers to any action that inhibits or delays diabetes by administration of a pharmaceutical composition of the present invention comprising a cane odor extract or a fraction thereof.
  • treatment refers to any action in which diabetes is improved or beneficially altered by administration of the pharmaceutical composition.
  • the results of comparing the efficacy of the bee-flavored odor with the same chrysanthemum Wanghae-guk or chamshu proved that the effect of the bee-flavored odor is significantly superior to the Wanghae-guk and chamcheuk (Fig. 3; compared to Wanghaeguk extract ### P ⁇ 0.001 / FIG. 4; compared to scent extract ### P ⁇ 0.001).
  • the pharmaceutical composition of the present invention may include 0.0001 to 80% by weight of the bee odor extract relative to the weight of the total composition, specifically may include 0.01 to 40% by weight, but is not limited thereto.
  • the pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier, excipient or diluent commonly used in the manufacture of the pharmaceutical composition, the carrier comprising a non-naturally occuring carrier. can do.
  • the pharmaceutical composition may be used in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral formulations, external preparations, suppositories, and sterile injectable solutions, respectively, according to conventional methods. .
  • “Pharmaceutically acceptable” means to exhibit properties that are not toxic to cells or humans exposed to the composition.
  • the type of the carrier is not particularly limited, and any carrier can be used as long as it is a conventionally used and pharmaceutically acceptable carrier in the art.
  • Non-limiting examples of the carrier include saline, sterile water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol, ethanol and the like. These may be used alone or in combination of two or more thereof.
  • ком ⁇ онентs such as antioxidants, buffers and / or bacteriostatic agents may be added and used, and diluents, dispersants, surfactants, binders, lubricants, and the like may be additionally added to provide a solution such as an aqueous solution, a suspension, an emulsion, or the like. It may be formulated into a use formulation, pills, capsules, granules or tablets.
  • the mode of administration of the pharmaceutical composition for preventing or treating diabetes mellitus according to the present invention is not particularly limited, and may be in accordance with methods commonly used in the art.
  • the composition may be administered by oral or parenteral administration.
  • the composition for preventing, ameliorating or treating diabetes of the present invention may be prepared in various formulations according to the desired mode of administration.
  • Another aspect provides a method of preventing or treating diabetes comprising administering the pharmaceutical composition to a subject.
  • the term "administration” means the introduction of certain substances into an individual in a suitable manner.
  • the term "individual” means all animals, such as rats, mice, and livestock, including humans who may or may have diabetes. As a specific example, it may be a mammal including a human.
  • the "individual” may include a companion animal.
  • the companion animal refers to an animal that lives together with a human, and includes, but is not limited to, a mammal such as a dog, a cat, a hamster, and a guinea pig, a bird such as a parrot, a canary, and the like.
  • the method for preventing or treating diabetes of the present invention may include administering to the individual a pharmaceutical composition comprising a bee-smelling extract or a fraction thereof in a pharmaceutically effective amount.
  • the "pharmaceutically effective amount” means an amount sufficient to treat the disease at a reasonable benefit / risk ratio applicable to the medical treatment and not causing side effects, and the effective dose level refers to the sex, age, weight, Well-known in the field and other medical fields, including health status, type of disease, severity, drug activity, drug sensitivity, method of administration, time of administration, route of administration, and rate of release, duration of treatment, combination or drug used simultaneously Depending on the factor, it can be readily determined by one skilled in the art.
  • the pharmaceutical composition of the present invention may be administered at 0.0001 to 500 mg / kg body weight per day, more specifically at 0.01 to 500 mg / kg body weight, based on solids. Dosing may include administering the recommended dose once a day or in several divided doses.
  • compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. It may also be single or multiple doses. Taking all of these factors into consideration it is important to administer an amount that will achieve the maximum effect in a minimum amount without causing side effects, which can be readily determined by one skilled in the art.
  • the route of administration and the mode of administration of the composition are not particularly limited, and any route of administration and administration can be achieved as long as the composition comprising the composition can reach the desired site. You can follow the way.
  • the composition may be administered through various routes, oral or parenteral, and non-limiting examples of the route of administration include oral, rectal, topical, intravenous, intraperitoneal, intramuscular, intraarterial, transdermal, nasal What is administered through intralateral or inhalation etc. are mentioned.
  • Yet another aspect of the present invention provides a food composition for preventing or improving diabetes comprising a bee anesthetist extract or a fraction thereof as an active ingredient.
  • the term " improvement" means any action that at least reduces the parameters associated with the condition to be treated with the administration of the compositions of the present invention, eg the extent of symptoms.
  • the term "food” of the present invention meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, drinks, tea, drinks, alcoholic beverages , Vitamin complexes, nutraceuticals and health foods, and includes all foods in the usual sense.
  • the food composition of the present invention can be consumed on a daily basis, a high diabetic improvement effect can be expected, and thus can be very useful for health promotion purposes.
  • the functional food is the same term as a food for special health use (Food for special health use, FoSHU), in addition to the nutritional supply, the processed food, so that the bioregulatory function appears efficiently, high medical effect Means food.
  • Food for special health use Food for special health use, FoSHU
  • the term 'function (sex)' refers to obtaining a useful effect for health purposes such as nutrient control or physiological action on the structure and function of the human body.
  • the food of the present invention can be prepared by a method commonly used in the art, and the preparation can be prepared by adding the raw materials and ingredients commonly added in the art.
  • the formulation of the food may be prepared without limitation as long as the formulation is recognized as a food.
  • Food composition of the present invention can be prepared in a variety of dosage forms, unlike the general medicine has the advantage that there is no side effect that can occur when taking a long-term use of the drug as a natural product, and because the portability is excellent, The food of the present invention can be taken as an adjuvant for enhancing the diabetic improvement effect.
  • the health food refers to foods having active health maintenance or promotion effect as compared to general foods
  • the health supplement food refers to foods for health supplementation purposes.
  • nutraceutical, health food, dietary supplement are used.
  • the health functional food is a food prepared by adding the compound of the present invention to food materials such as beverages, teas, spices, gums, confections, or the like, encapsulated, powdered, suspensions, etc.
  • food materials such as beverages, teas, spices, gums, confections, or the like, encapsulated, powdered, suspensions, etc.
  • the food composition may further include a physiologically acceptable carrier, and the type of carrier is not particularly limited and may be any carrier that is commonly used in the art.
  • the food composition may include additional ingredients that are commonly used in food compositions to improve the smell, taste, time and the like.
  • additional ingredients may include vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid, and the like.
  • minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu) and chromium (Cr); And amino acids such as lysine, tryptophan, cysteine, valine and the like.
  • the food composition is a preservative (potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetic acid, etc.), fungicides (bleaching powder and highly bleaching powder, sodium hypochlorite, etc.), antioxidants (butylhydroxyanisol (BHA), butylhydride) Oxytoluene (BHT), etc.), colorant (such as tar pigment), colorant (sodium nitrite, sodium nitrite, etc.), bleach (sodium sulfite), seasoning (MSG glutamate, etc.), sweetener (ducin, cyclate, saccharin Foods such as sodium, etc.), fragrances (vanillin, lactones, etc.), swelling agents (alum, potassium D-tartrate, etc.), reinforcing agents, emulsifiers, thickeners (foils), coatings, gum herbicides, foam inhibitors, solvents, modifiers, etc. It may include food additives.
  • the additive may be
  • An example of the food composition of the present invention may be used as a health beverage composition, in which case it may contain various flavors or natural carbohydrates and the like as additional ingredients, such as a general beverage.
  • the above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; Polysaccharides such as dextrin, cyclodextrin; Sugar alcohols such as xylitol, sorbitol, and erythritol.
  • Sweeteners include natural sweeteners such as taumartin, stevia extract; Synthetic sweeteners such as saccharin and aspartame;
  • the ratio of the natural carbohydrate may be generally about 0.001 to 0.4 g, specifically about 0.002 to 0.3 g per 100 mL of the health beverage composition of the present invention.
  • the health beverage composition includes various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, Alcohol or carbonation agent and the like.
  • Others may contain fruit flesh for the production of natural fruit juices, fruit juice drinks, or vegetable drinks. These components can be used independently or in combination. Although the ratio of such an additive is not critical, it is generally selected in the range of 0.001 to 0.10 parts by weight per 100 parts by weight of the health beverage composition of the present invention.
  • Another aspect of the present invention provides a feed composition for the prevention or improvement of diabetes mellitus including a bee herb extract or fractions thereof as an active ingredient.
  • composition comprising the bee anesthetized extract of the present invention or a fraction thereof may be used for preventing or treating diabetes onset in a subject other than humans, such as livestock or a companion animal, and may be utilized as a functional feed additive or a feed composition.
  • the content of the bee-flavored extract or fractions thereof in the feed composition according to the present invention can be appropriately adjusted according to the type and age of the livestock, the type of application, the desired effect, and the like, for example, 1 to 99% by weight, preferably 10 to 90% by weight. %, More preferably 20 to 80% by weight, but is not limited thereto.
  • diluents, dispersants, surfactants, binders or lubricants may be additionally added to formulate injectable formulations, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
  • the feed composition of the present invention is a supplementary ingredient such as amino acids, inorganic salts, vitamins, antioxidants, antifungal agents, antibacterial agents, and vegetable protein feed such as milled or crushed wheat, barley, corn, blood meal, meat meal, fish meal as auxiliary ingredients.
  • a supplementary ingredient such as amino acids, inorganic salts, vitamins, antioxidants, antifungal agents, antibacterial agents, and vegetable protein feed such as milled or crushed wheat, barley, corn, blood meal, meat meal, fish meal as auxiliary ingredients.
  • animal protein feed animal fat and vegetable fat, such as can be used with nutritional supplements, growth promoters, digestive absorption accelerators, disease prevention agents.
  • the feed composition of the present invention When the feed composition of the present invention is used as a feed additive, the feed composition may be added as it is or used together with other ingredients, and may be suitably used according to a conventional method.
  • Dosage forms of the feed composition may be prepared in immediate release or sustained release formulation in combination with a nontoxic pharmaceutically acceptable carrier.
  • a nontoxic pharmaceutically acceptable carrier may be corn starch, lactose, sucrose, propylene glycol.
  • a solid carrier it may be a dosage form such as a tablet, a powder, a torokee agent, or the like, and in the case of a liquid carrier, it may be a dosage form of a syrup, a liquid suspension, an emulsion, or a solution.
  • the dosage may contain preservatives, lubricants, solution promoters, stabilizers, and may also contain other inflammatory disease ameliorating agents and substances useful for virus prevention.
  • the feed composition of the present invention is applicable to a number of animal diets, ie feeds, including mammals, poultry, fish and shellfish.
  • animal diets including mammals, poultry, fish and shellfish.
  • Commercially important mammals such as pigs, cows and goats, zoo animals such as elephants and camels, and livestock such as dogs and cats.
  • Commercially important poultry includes chickens, ducks, geese and the like, and may include commercially raised fish and crustaceans such as trout and shrimp.
  • the feed composition according to the present invention may be mixed in a livestock feed in an amount of about 10 to 500 g, preferably 10 to 100 g per kg, on a dry weight basis, and then thoroughly mixed and then fed into a mesh or further processing. Palletization, expansion, extrusion through the process is preferred.
  • KIOM83A a bee-flavored alcohol extract
  • the KIOM83A was separated into hexane, ethyl acetate, butanol, and water, and the hexane layer (KIOM-83H), the ethyl acetate layer (KIOM-83EA), the butanol layer (KIOM-83Bu), and the water layer (KIOM-) of the bee odor extract were extracted.
  • 83W was obtained.
  • Aster scaber Thunb. (Wing leaf squirrel) was purchased and purchased in July 2016 from Sanju Botanical Garden of Chungju, Chungju, Korea and stored in a low temperature room for sample storage at Korea Institute of Oriental Medicine (Daejeon, Korea).
  • sesame extract manufacturing process 5 g of sesame seed was added to 50 mL of primary distilled water corresponding to 10 times the weight to prepare hot water extract, filtration, and concentrated freeze-dried extract at 100 ° C.
  • Wang Hae- guk ( Aster spathulifolius var. Pharai ) was purchased and used in Chungcheongju National Petrochemical Botanical Garden in July 2016, and was stored in the low temperature room for sample storage of Korea Institute of Oriental Medicine (Daejeon, Korea).
  • Wanghaeguk is a plant belonging to Aster spathulifolius .
  • Wanghaeguk extract manufacturing process 5g of Wanghaeguk was added to 50 mL of primary distilled water corresponding to 10 times the weight, and hot water extraction, filtration and concentrated freeze-dried extracts were prepared at 100 ° C.
  • Adipose precursor cells 3T3-L1 were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA), and all the media used for cell culture were purchased from WELGENE.
  • the progenitor cells were cultured at 37 ° C. and 5% CO 2 using Dulbecco's modified Eagle's medium (DMEM) containing 1% P / S (penicillin-streptomycin) and 10% FBS.
  • DMEM Dulbecco's modified Eagle's medium
  • Cultivation was carried out at 3 days intervals, when cells were grown to about 80% at the bottom of a 100 mm plate, washed with PBS (phosphate buffered saline), 0.25% trypsin-EDTA solution was added at 37 °C, 5% CO 2 conditions 3 Cells were detached and passaged and maintained by treatment for a minute.
  • PBS phosphate buffered saline
  • trypsin-EDTA solution was added at 37 °C, 5% CO 2 conditions 3 Cells were detached and passaged and maintained by treatment for a minute.
  • Example 7 Beetle anesthetic extracts ( ASKO , ASKO -30, ASKO -50, ASKO -80, KIOM83A , KIOM-83H, KIOM - 83EA , KIOM - 83Bu , KIOM -83W) hypoglycemic effect
  • adipocytes were prepared by differentiating 3T3-L1, an adipocyte.
  • 3T3-L1 an adipocyte
  • the differentiated adipocytes were cultured in low concentration glucose medium without FBS, and were treated with ASKO, ASKO-30, ASKO-50, ASKO-80, KIOM83A, KIOM-83H, KIOM-83EA, KIOM-83Bu, KIOM-83W.
  • Each concentration was treated and glucose uptake was analyzed using Glucose Uptake Cell-Based Assay Kit (Cayman Chemical Company, MI, USA). At this time, the result was measured in the fluorescence analyzer 485/535 nm.
  • Example 8 Beetle Anesthetic Extracts Wanghae Guk Verification of extract and hypoglycemic
  • the bee anesthetized extract such as ASKO, ASKO-30, KIOM83A, KIOM-83H, KIOM-83Bu promotes glucose absorption of adipocytes during blood sugar rise, thereby maintaining excellent blood sugar. Since it has modulating activity, it can be seen that it can be usefully used as a composition for preventing and treating diabetes. In addition, it can be seen that the effect is significantly superior to the plants of the same genus Hwanghaeguk and chamcheuk.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medical Informatics (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition comprenant un extrait d'Aster Koraiensis ou une fraction de ce dernier en tant que principe actif pour prévenir ou traiter le diabète et, plus particulièrement, une composition pharmaceutique comprenant un extrait d'Aster Koraiensis ou une fraction de ce dernier en tant que principe actif pour prévenir ou traiter le diabète, une composition alimentaire, et un procédé de prévention ou de traitement du diabète à l'aide de la composition pharmaceutique. L'extrait d'Aster Koraiensis de la présente invention présente un effet de réduction de la glycémie en favorisant l'absorption du glucose par les adipocytes, et peut donc être avantageusement utilisé dans la prévention ou le traitement du diabète. De plus, la composition de la présente invention est dérivée d'une substance naturelle, et peut donc être utilisée en toute sécurité sans aucun effet secondaire pour la régulation de la glycémie et la prévention, le traitement et le soulagement du diabète.
PCT/KR2017/007231 2016-07-08 2017-07-06 Composition comprenant un extrait d'aster koraiensis ou une fraction de ce dernier en tant que principe actif servant à la régulation de la glycémie et à la prévention ou au traitement du diabète Ceased WO2018008999A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160086606 2016-07-08
KR10-2016-0086606 2016-07-08

Publications (1)

Publication Number Publication Date
WO2018008999A1 true WO2018008999A1 (fr) 2018-01-11

Family

ID=60913013

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/007231 Ceased WO2018008999A1 (fr) 2016-07-08 2017-07-06 Composition comprenant un extrait d'aster koraiensis ou une fraction de ce dernier en tant que principe actif servant à la régulation de la glycémie et à la prévention ou au traitement du diabète

Country Status (2)

Country Link
KR (1) KR20180006612A (fr)
WO (1) WO2018008999A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102449272B1 (ko) * 2019-12-24 2022-09-29 (주)메이준생활건강 벌개미취 추출물을 포함하는 비알콜성 지방간염의 예방 또는 치료용 약학 조성물
KR102705574B1 (ko) * 2021-05-27 2024-09-11 대한민국 선씀바귀 추출물 및 벌개미취 추출물을 유효성분으로 포함하는 당뇨, 이상지질혈증, 지방간 및 인슐린 저항성 증후군으로 이루어진 대사질환의 예방 및 치료용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008111763A1 (fr) * 2007-03-09 2008-09-18 Korea Institute Of Oriental Medicine Extraits de aster koraiensis et composition pharmaceutique et aliment fonctionnel les contenant
KR20100115598A (ko) * 2009-04-20 2010-10-28 경희대학교 산학협력단 잣나무잎 추출물을 유효성분으로 함유하는 당뇨질환의 예방 및 치료용 조성물
JP2011012021A (ja) * 2009-07-02 2011-01-20 Firstvision Co Ltd 血糖コントロール用組成物
KR101540107B1 (ko) * 2015-02-05 2015-07-30 주식회사 다림바이오텍 반복적 희석 및 진탕을 이용한 경구용 제제의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050048299A (ko) * 2003-11-19 2005-05-24 대한민국(광주.전남지방중소기업청) 항균 및 항염 효능을 갖는 염료 및 그 염료가 염색된 화장지
KR20110038375A (ko) * 2009-10-08 2011-04-14 한림대학교 산학협력단 벌개미취추출물을 포함하는 통증 치료용 조성물 및 그 제조 방법
KR101187032B1 (ko) * 2010-05-18 2012-09-28 한국과학기술연구원 벌개미취의 추출물, 분획물 또는 이로부터 분리한 짐나스테르코리아인 ｂ 화합물을 유효성분으로 함유하는 간 보호 또는 개선용 조성물
KR101391308B1 (ko) * 2011-02-18 2014-05-07 한국과학기술연구원 벌개미취 추출물 또는 이의 분획물을 포함하는 망막질환 예방 및 치료용 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008111763A1 (fr) * 2007-03-09 2008-09-18 Korea Institute Of Oriental Medicine Extraits de aster koraiensis et composition pharmaceutique et aliment fonctionnel les contenant
KR20100115598A (ko) * 2009-04-20 2010-10-28 경희대학교 산학협력단 잣나무잎 추출물을 유효성분으로 함유하는 당뇨질환의 예방 및 치료용 조성물
JP2011012021A (ja) * 2009-07-02 2011-01-20 Firstvision Co Ltd 血糖コントロール用組成物
KR101540107B1 (ko) * 2015-02-05 2015-07-30 주식회사 다림바이오텍 반복적 희석 및 진탕을 이용한 경구용 제제의 제조방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SU , JUN: "Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice", ARTERIOSCLERSIS, THROMBOSIS, AND VASCULAR BIOLOGY, 2008, pages 1432 - 1438, XP055601900 *

Also Published As

Publication number Publication date
KR20180006612A (ko) 2018-01-18

Similar Documents

Publication Publication Date Title
KR102081984B1 (ko) 새싹밀 추출물을 포함하는 골다공증 예방 또는 치료용 조성물
WO2015002391A1 (fr) Composition présentant une fonction d'atténuation du syndrome prémenstruel et des douleurs menstruelles
KR20220162654A (ko) 노각나무 추출물을 유효성분으로 포함하는 시력 보호용 또는 망막 질환의 개선 및 예방용 조성물
KR102519649B1 (ko) 캠퍼롤 및 에피카테킨 갈레이드를 포함하는 홍경천 추출물을 포함하는 전립선 관련 질환의 예방 또는 치료용 조성물
KR101187032B1 (ko) 벌개미취의 추출물, 분획물 또는 이로부터 분리한 짐나스테르코리아인 ｂ 화합물을 유효성분으로 함유하는 간 보호 또는 개선용 조성물
KR102147101B1 (ko) 금전초 추출물을 포함하는 신경세포 보호용 조성물
WO2018008999A1 (fr) Composition comprenant un extrait d'aster koraiensis ou une fraction de ce dernier en tant que principe actif servant à la régulation de la glycémie et à la prévention ou au traitement du diabète
KR102379612B1 (ko) 갈색거저리 유충 발효 추출물을 포함하는 골다공증 예방 또는 치료용 조성물
WO2016190566A2 (fr) Composition pharmaceutique ou aliment naturel fonctionnel pour la prévention et le traitement de maladies métaboliques, contenant un extrait aqueux de pleurotus eryngii var. ferulae (pf.) en tant que principe actif
KR102414431B1 (ko) 엉겅퀴, 민들레, 여주, 돼지감자, 양파, 꾸지뽕, 아로니아 및 생강을 포함하는 당뇨의 예방, 치료 또는 개선용 조성물
KR102072471B1 (ko) 벌개미취 추출물 또는 이의 분획물을 유효성분으로 포함하는 파킨슨병의 예방 또는 치료용 조성물
WO2018066956A1 (fr) Composition comprenant un extrait composite contenant du schisandrae fructus pour prévenir ou traiter une maladie liée à la circulation sanguine
WO2017082479A1 (fr) Composition pharmaceutique destinée à la prévention ou au traitement de l'obésité comprenant un extrait embryonnaire de fève germée
WO2023191249A1 (fr) Composition pour atténuer l'obésité ou le métabolisme des lipides comprenant un extrait d'asimina triloba
WO2012105816A2 (fr) Composition destinée à prévenir et traiter le diabète et les complications du diabète comprenant une poudre d'amphicarpaea edgeworthii var. trisperma ou un extrait de celle-ci
WO2021261707A1 (fr) Composition de soulagement, de traitement, ou de prévention des maladies musculaires, ou d'amélioration des fonctions musculaires, contenant de l'extrait de menthe coréenne ou de la tilianine en tant que principe actif
KR102157413B1 (ko) 톱니모자반 추출물을 유효성분으로 포함하는 간 보호, 간질환 예방 또는 치료용 조성물
KR101896815B1 (ko) 식욕부진 개선용 건강기능식품 조성물 및 식욕부진 예방 또는 치료용 약학 조성물
WO2020246863A1 (fr) Composition comprenant du chlorhydrate de cudrania comme composant efficace pour soulager, traiter ou prévenir les maladies musculaires, ou améliorer les fonctions musculaires
WO2025048076A1 (fr) Composition comprenant un extrait de fomitopsis pinicola en tant que principe actif pour le traitement ou la prévention d'une maladie cérébrale ischémique et son utilisation
KR102092961B1 (ko) 미선나무 에탄올 추출물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품
KR20190036338A (ko) 고들빼기 추출물을 포함하는 간 보호용 조성물
WO2025110266A1 (fr) Utilisation d'un extrait de stewartia pseudocamellia pour protéger la vue ou soulager, prévenir ou traiter les maladies rétiniennes
WO2018174502A1 (fr) Composition pharmaceutique pour le traitement prophylactique ou thérapeutique du diabète comprenant un extrait de feuille de chrysanthème en tant que principe actif
KR102143968B1 (ko) 산초 추출물을 포함하는 중성지방에 의한 대식세포 사멸 억제용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17824555

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17824555

Country of ref document: EP

Kind code of ref document: A1